207_Combined course Presentations
Tri als with Panitumumab/RT in anal cancer
Trial
N of patients
IMRT Regimen
Toxicity Efficacy
At 24 weeks 55% had CR
Feliu et al, ASCO 2014 GEMCAD 09-02
58
No 45 Gy + boost of 10-15 Gy
5-FU/MMC +RT + panitumumab
High 33/36 (92%) G3/4 AE
Made with FlippingBook